Thursday, 3 November 2022

Alembic receives approval from the USFDA for Ketorolac Tromethamine

Alembic receives approval from the USFDA for Ketorolac Tromethamine
Alembic receives approval from the USFDA for Ketorolac Tromethamine

Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) Single Dose Vials.

This is the second injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.

admin Thu, 11/03/2022 - 16:21

source https://www.pharmatutor.org/pharma-news/2022/alembic-receives-approval-from-the-usfda-for-ketorolac-tromethamine

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...